Management of INR 3.83 and PT 54 seconds
For a patient with INR 3.83 (no bleeding), hold the next 1-2 doses of warfarin and restart at a lower dose when INR approaches therapeutic range; if the patient has bleeding risk factors, add oral vitamin K 1-2.5 mg. 1
Clinical Assessment Priority
First, immediately assess for active bleeding and bleeding risk factors:
- Age ≥65 years
- History of stroke or gastrointestinal bleeding
- Renal insufficiency or anemia
- Concomitant antiplatelet agents (aspirin, NSAIDs)
- Recent trauma or planned procedures 1
The presence or absence of these factors determines your management pathway.
Management Algorithm Based on Bleeding Status
No Active Bleeding, No High-Risk Features
- Hold warfarin for 1-2 doses
- Recheck INR in 24-48 hours
- Resume warfarin at a lower dose when INR falls into therapeutic range
- No vitamin K needed in this scenario 1
This approach is supported by evidence showing that slightly out-of-range INRs managed with watchful waiting versus dose changes have similar outcomes (predicted probability of returning to range: 58.9% vs 60.0%) 2. However, at INR 3.83, you're approaching the threshold where intervention becomes more beneficial.
No Active Bleeding, BUT Patient Has Bleeding Risk Factors
- Hold next dose of warfarin
- Give oral vitamin K 1-2.5 mg
- Recheck INR in 24 hours
- Resume warfarin at lower dose when INR approaches therapeutic range 1
The guideline specifically states this approach "should be used if the patient is at increased risk of bleeding" 1. Oral vitamin K at this dose effectively reduces INR without causing warfarin resistance—in one study, 95% of patients had lower INR at 24 hours, 85% achieved INR <4, and none developed resistance when warfarin was resumed 1.
Active Non-Severe Bleeding
- Stop warfarin
- Give oral vitamin K 3-5 mg
- Anticipate INR fall within 24-48 hours
- Monitor INR closely and repeat vitamin K as necessary 1
Severe Bleeding or Life-Threatening Hemorrhage
- Stop warfarin immediately
- Give vitamin K 10 mg by slow IV infusion (over 30 minutes)
- Administer prothrombin complex concentrate (PCC) 25 IU/kg or fresh frozen plasma
- Recheck INR within 30 minutes, then at 6-8 hours and 24 hours
- May need additional vitamin K every 12 hours 1, 3
Critical Pitfalls to Avoid
Do NOT give high-dose vitamin K (10 mg) for non-bleeding patients with INR 3.83—this creates warfarin resistance lasting up to a week and may induce a hypercoagulable state 1, 4. The 2008 ACC/AHA guidelines explicitly state this as a Class III recommendation (should not be done) 4.
Avoid IV vitamin K unless absolutely necessary for severe bleeding—it carries risk of anaphylaxis, though rare. Oral administration is "predictably effective and has the advantages of convenience and safety over parenteral routes" 1.
Do not use subcutaneous vitamin K—response is "unpredictable and sometimes delayed" 1.
Monitoring Strategy
- Recheck INR in 24 hours after vitamin K administration (if given)
- Monitor for occult bleeding: check hemoglobin if any clinical suspicion
- Assess for underlying causes: new medications, dietary changes, acute illness, liver dysfunction
- When restarting warfarin, reduce dose by approximately 10-20% and recheck INR in 3-5 days 1
Context for This INR Level
An INR of 3.83 significantly increases bleeding risk compared to therapeutic range (2.0-3.0). Studies demonstrate that lowering INR from 3.0-4.5 range to 2.0-3.0 range "reduces the risk of clinically significant bleeding" with only about 1 mg/day less warfarin needed 1. At INR >2.75, thromboembolic complications are rare, but hemorrhagic complications increase substantially above INR 3.0 5.
The mortality risk becomes particularly concerning if bleeding occurs—hemoglobin drops ≥2 g/dL or transfusion requirements ≥2 units are associated with significantly increased mortality, especially in patients with cardiovascular disease 6.